Curanex Pharmaceuticals Inc’s (NASDAQ:CURX) Lock-Up Period Set To Expire on February 23rd

Curanex Pharmaceuticals’ (NASDAQ:CURX) lock-up period is set to expire on Monday, February 23rd. Curanex Pharmaceuticals had issued 3,750,000 shares in its IPO on August 26th. The total size of the offering was $15,000,000 based on an initial share price of $4.00. After the expiration of the company’s lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. Wall Street Zen downgraded shares of Curanex Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, November 22nd. Weiss Ratings reiterated a “sell (e-)” rating on shares of Curanex Pharmaceuticals in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Curanex Pharmaceuticals presently has a consensus rating of “Sell”.

Curanex Pharmaceuticals Price Performance

Shares of NASDAQ CURX opened at $0.28 on Wednesday. The stock has a market capitalization of $7.99 million and a P/E ratio of -5.64. The business’s fifty day moving average price is $0.35. Curanex Pharmaceuticals has a 1 year low of $0.26 and a 1 year high of $9.18.

Institutional Trading of Curanex Pharmaceuticals

A hedge fund recently bought a new stake in Curanex Pharmaceuticals stock. Citadel Advisors LLC acquired a new position in shares of Curanex Pharmaceuticals Inc (NASDAQ:CURX) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 64,067 shares of the company’s stock, valued at approximately $46,000.

About Curanex Pharmaceuticals

Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections.